Clinical Trial Update: A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating subcutaneous guselkumab for active psoriatic arthritis has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Arthritis Psoriatic
• Psoriatic Arthritis

Drugs mentioned

• Guselkumab (guselkumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Arthritis, Psoriatic | Phase 3 | Status: COMPLETED | Results posted: 2020-11-05